IVIG

Although it is currently used off-label for many neuroinflammatory and neurodegenerative disorders, intravenous immunoglobulin is showing promise for a growing number of neurological diseases.

A metanalysis published in SN Comprehensive Clinical Medicine found that administering the therapies early in a patient’s treatment could be associated with better outcomes.

The duration for body temperature normalization, oxygen saturation, and mechanical ventilation were significantly shorter for patients who received IVIG in addition to standard of care (SOC) when compared to those only receiving SOC.

Home infusion within the larger ambulatory infusion setting poses some specific advantages and disadvantages in relation to the other location options available.

If IVIG is commenced within 2 weeks from the onset of Guillain-Barre syndrome it can hasten recovery as much as plasma exchange, study indicates.

Researchers find no clear therapeutic benefit of intravenous immunoglobulin for the prevention of postnatal relapses of multiple sclerosis.

The availability of both intravenous and subcutaneous routes of immunoglobulin has made personalization of treatment more important than ever.

Pfizer's drug product is the first FDA-approved intravenous immunoglobulin with 2 maintenance dosing options for CIDP.

Early experiments through the 19th century theorized local injection with human rabies immunoglobulin at the wound site provided better effects at neutralizing the virus.

The objective of the study was to develop a method for de-escalation of intravenous (IV) vancomycin in patients receiving vancomycin with at least 1 other antibiotic appropriate for the treatment of community-acquired pneumonia (CAP).

Intravenous immunoglobulin administered to hypoxic non-ventilated COVID-19 patients with an A-a gradient of more than 200 mg Hg significantly decreases the rates of progression to mechanical ventilation.

Xolair provides an alternative to surgery or steroids for the treatment of nasal polyps in adults.

The findings show that vaping changes the expression of genes and production of proteins in respiratory cells, as well as altering virus-specific antibody production, according to the study.

Although a single IVIG dose of 25 g was effective in most cases, for some strains repeated doses were necessary to achieve a significant reduction in superantigenic responses.

Both intravenous immunoglobulin and subcutaneous immunoglobulin are effective in treating myasthenia gravis.

Providers must account for important considerations when choosing the appropriate therapy for each patient based on their specific needs.

The trial’s main goal is to compare the health status of participants in the combination treatment group with participants in the remdesivir-only group on day 7.

Although researchers still hope to learn what protection immunoglobulin G antibodies offer against re-infection, this study could have broad implications in the development of a COVID-19 vaccine.

Intravenous Immunoglobulin helps to improve hypoxia, which can reduce the need for mechanical ventilation.

When treating these diseases, immunoglobulin is effective because of its ability to be used by the immune system to neutralize pathogens, such as pathogenic bacteria, fungi, and viruses.

Myasthenia gravis is most commonly caused by binding of immunoglobulin G (IgG) antibodies to the postsynaptic acetylcholine receptor (AChR), although other receptors may also be involved.

A study found that intravenous immune globulin dosing optimization through alternative dosing weights represents a significant source of waste reduction and cost reduction.

In this study, researchers wanted to evaluate the frequency of reduced immunoglobulin concentrations and its association with immunotherapy and disease course in 2 independent cohorts with multiple sclerosis.

Carefully implemented order sets may encourage evidence-based or institution-specific care though the influence of provider behavior.

Five-day adjuvant IVIG therapy found to significantly reduce viral load in an immunocompromised patient with severe varicella.

The case study included a 45-year-old man diagnosed with stage 3 multiple myeloma who was treated with bortezomib and dexamethasone.

The study authors wanted to determine the prevalence and clinical significances of red blood cell-bound immunoglobulin G as detected by flow cytometry in polytransfused patients with thalassemia.

IVIG found to have a good safety profile in pediatric patients, with low risk of severe adverse drug reactions.

Study is the first to identify the presence of anti-citrullinated protein autoantibodies in human tear fluid as well as discover the new eye drop treatment.

Study seeks to determine the prevalence and clinical significance of red blood cell-bound immunoglobulin G as detected by flow cytometry in polytransfused patients with thalassemia.